Cancer metastasis is responsible for the vast majority of cancer‐related deaths worldwide.
In contrast to numerous discoveries that reveal the detailed mechanisms leading to the …

New York esophageal squamous cell carcinoma-1 (NY-ESO-1)-specific T cell receptor (TCR)
T cell therapy is effective in tumors with NY-ESO-1 expression, but a safe and effective TCR…

Objective To elucidate the role and prognostic significance of lymphocyte activation-gene-3 (LAG-3)
in soft tissue sarcoma (STS). Methods The expression of LAG-3 in patient and …

Background No standard maintenance treatment has been obtained to prolong the response
duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed …

Background New immunotherapeutic approaches are urgently needed for metastatic
rhabdomyosarcoma, which is associated with poor survival and unsatisfactory treatment outcomes. …

Objectives To explore the predictive value of inflammatory‐nutritional score (INS) and a
nomogram for survivals in head and neck soft tissue sarcoma (HNSTS) patients with negative …

11502 Background: NY-ESO-1 is a cancer/testis antigen with expression in a wide range of
tumor types. TAEST16001 cells are genetically engineered autologous T cells that express …

Background: Palliative chemotherapy is currently the first-line treatment for advanced soft
tissue sarcoma. The purpose of this study was to compare the efficacies of the MAID (AI) and …

e23540 Background: Surufatinib is a multi-targeted, small-molecule tyrosine kinase inhibitor
(TKI) that shows strong inhibitory effect on the activity of VEGFR-1, 2, 3, FGFR1 and CSF-1R…

11566 Background: Chidamide is an oral subtype-selective histone deacetylase inhibitor
which is effective on the patients with hematological tumors and reported to enhance the …